PainEarly Phase 1NCT01595620
Cannabinoid Modulation of Pain
A Early Phase 1 study testing Thermal, Electrical and Capsaicin in people with Pain, run by Yale University at 1 site in United States.
Trial summary
The purpose of this study is to test the effects of cannabinoids on pain response using a variety of human experimental pain models. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Pain
- What is being tested?
- Thermal, Electrical and Capsaicin
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 6 participants
- Where
- 1 siteUnited States
- Study dates
- 9 Nov 2011to 19 Apr 2012
- Phase
- Early Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- At least one lifetime exposure to cannabis
- Acceptable Birth Control methods for females
Who cannot join
- Cannabis naive
- Medical or psychiatric contraindications
- Analgesic medication
- Previous sensitivity to THC or cannabis
Trial locations and contacts
1 site in 1 country.
United States1 site
VA Connecticut Healthcare System
West Haven, Connecticut, 06516
About this study
The purpose of this study is to test the effects of cannabinoids on pain response using a variety of human experimental pain models.
- Conditions
- Pain
- Being tested
- Thermal, Electrical, Capsaicin, THC, Placebo
- Keywords
- Cannabis, THC, Pain
- Medical subject headings
- Pain, Marijuana Abuse
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ThermalOther
Thermal sensation/pain testing
ElectricalOther
Electrical sensation/pain testing
CapsaicinOther
Intradermal Capsaicin
THCDrug
Also called Delta-9-tetrahydrocannabinol
Active THC (0.01 mg/kg) administered over 10 minutes
THCDrug
Also called Delta-9-tetrahydrocannabinol
Active THC (0.03 mg/kg) administered over 10 minutes
PlaceboDrug
Control: small amount of alcohol with no THC, administered over 10 minutes
| Study group | Role | What they receive |
|---|---|---|
| THC 0.01 mg/kg | Active comparator | Not described Receives: Other: Thermal; Other: Electrical; Other: Capsaicin; Drug: THC |
| Placebo | Placebo comparator | Not described Receives: Other: Thermal; Other: Electrical; Other: Capsaicin; Drug: Placebo |
| THC 0.03 mg/kg | Active comparator | Not described Receives: Other: Thermal; Other: Electrical; Other: Capsaicin; Drug: THC |
What is being measured
The primary outcome is the main question the study is designed to answer.
Capsaicin-induced hyperalgesia
Measured: On each test day at baseline (-30), peak (+20) and post (+120) drug administration
Secondary outcomes (3)
Pain Measures
Measured: On each test day at baseline (-30), peak (+20) and post (+120) drug administration
Non-pain subjective responses
Measured: On each test day at baseline (-30), peak (+20) and post (+120) drug administration
Cognitive subjective responses
Measured: On each test day at baseline (-30), peak (+20) and post (+120) drug administration
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 May 2012 (estimated)
- Study start9 Nov 2011
- Primary completion19 Apr 2012
- Study completion19 Apr 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PainStudies of the same condition, open and under way.
- More trials run by Yale UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 6 participants (actual)
Sponsor and investigators
- Lead sponsor
- Yale University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Deepak C. D'Souza, Yale University
- Investigators
- Deepak C D'Souza, M.D., Principal investigator, Yale University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01595620
- Sponsor's protocol ID
- 1005006859
- Status last verified
- Feb 2022
- First submitted
- 25 Apr 2012
- Last updated
- 9 Mar 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Mar 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cannabinoid Modulation of Pain
- ClinicalTrials.gov ID
- NCT01595620
- Acronym / sponsor ID
- 1005006859
- Conditions
- Pain
- Keywords
- Cannabis, THC, Pain
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 6 participants (actual)
- Lead sponsor
- Yale UniversityUniversity, hospital or other
- Study start
- 9 Nov 2011 (actual)
- Primary completion
- 19 Apr 2012 (actual)
- Study completion
- 19 Apr 2012 (actual)
- First posted
- 10 May 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to test the effects of cannabinoids on pain response using a variety of human experimental pain models.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| THC 0.01 mg/kg | Active comparator | Other: Thermal, Other: Electrical, Other: Capsaicin, Drug: THC |
| Placebo | Placebo comparator | Other: Thermal, Other: Electrical, Other: Capsaicin, Drug: Placebo |
| THC 0.03 mg/kg | Active comparator | Other: Thermal, Other: Electrical, Other: Capsaicin, Drug: THC |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- At least one lifetime exposure to cannabis
- Acceptable Birth Control methods for females
Key exclusion criteria (4 listed)
- Cannabis naive
- Medical or psychiatric contraindications
- Analgesic medication
- Previous sensitivity to THC or cannabis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ThermalThermal sensation/pain testing | Other | Placebo, THC 0.01 mg/kg, THC 0.03 mg/kg |
| ElectricalElectrical sensation/pain testing | Other | Placebo, THC 0.01 mg/kg, THC 0.03 mg/kg |
| CapsaicinIntradermal Capsaicin | Other | Placebo, THC 0.01 mg/kg, THC 0.03 mg/kg |
| THCAlso: Delta-9-tetrahydrocannabinolActive THC (0.01 mg/kg) administered over 10 minutes | Drug | THC 0.01 mg/kg |
| THCAlso: Delta-9-tetrahydrocannabinolActive THC (0.03 mg/kg) administered over 10 minutes | Drug | THC 0.03 mg/kg |
| PlaceboControl: small amount of alcohol with no THC, administered over 10 minutes | Drug | Placebo |
Primary outcome
Capsaicin-induced hyperalgesia
Time frame: On each test day at baseline (-30), peak (+20) and post (+120) drug administration
3 secondary outcomes
Pain Measures
Time frame: On each test day at baseline (-30), peak (+20) and post (+120) drug administration
Non-pain subjective responses
Time frame: On each test day at baseline (-30), peak (+20) and post (+120) drug administration
Cognitive subjective responses
Time frame: On each test day at baseline (-30), peak (+20) and post (+120) drug administration
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Mar 2022.
Related trials for Pain
Not yet recruiting
Digital Use, 24-Hour Movement Behaviors, and Myofascial Release in University Students With Neck Pain
Forward Head Posture, Chronic Nonspecific Neck Pain
Recruiting
Effects of Virtual Reality Exergames Versus Spinal Manipulation in Chronic Nonspecific Low Back Pain
Chronic Nonspecific Low-back Pain, CNSLBP
Recruiting
Dietary Intervention for Migraine Relief
Migraine
RecruitingPhase 4
Anrikefon-based Patient-controlled Intravenous Analgesia Following Laparoscopic Surgery
Laparoscopic Surgery, Visceral Pain, Postoperative
Not yet recruiting
Ultrasound-Guided Radiofrequency Ablation for Focal Adenomyosis
Adenomyosis, Adenomyoma of Uterus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Deepak C D'Souza, M.D. principal investigator
Yale University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing Thermal, Electrical and Capsaicin in people with Pain, run by Yale University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Capsaicin-induced hyperalgesia (time frame: On each test day at baseline (-30), peak (+20) and post (+120) drug administration). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Mar 2022.